2023 World Conference on Lung Cancer (Posters)-P2.09. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)

P2.09. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

Pdf Summary

This study investigated the impact of TP53 variants in HER2-mutated non-small cell lung cancer (NSCLC) and its effect on treatment outcomes. The researchers reviewed 82 patients with HER2-mutated NSCLC and analyzed the association between TP53 status and baseline demographics, overall response rate (ORR), survival (OS), and progression-free survival (PFS). TP53/HER2 co-mutations were found in 48% of the cohort.<br /><br />The results showed that TP53 variants were predictive of a poor response to targeted treatments. The ORR to targeted treatment was similar between TP53 wildtype (WT) and variant cohorts. However, fewer patients in the TP53-WT cohort had progressive disease as the best response. The median PFS was shorter in the TP53-mutated cohort compared to the WT cohort, indicating a poorer prognosis. The median OS was also shorter in the TP53-mutated cohort compared to the WT cohort. Additionally, there was a tendency for a higher incidence of brain metastases in patients with TP53 variants.<br /><br />The study concludes that co-occurring TP53 variants with HER2 mutations in NSCLC are predictive of a poor response to targeted treatments and are associated with shorter OS and PFS. Furthermore, these variants may be linked to a higher incidence of brain metastases.<br /><br />This research provides valuable insights into the impact of TP53 variants on treatment outcomes in HER2-mutated NSCLC. Understanding the role of TP53 in this context has significant implications for personalized treatment strategies and prognosis prediction in patients with HER2-mutated NSCLC.

Asset Subtitle

Jamie Feng

Meta Tag

Speaker Jamie Feng

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

TP53 variants

HER2-mutated non-small cell lung cancer

treatment outcomes

overall response rate

survival

progression-free survival

TP53/HER2 co-mutations

targeted treatments

prognosis prediction

brain metastases